Editing Breast cancer (section)

=== Medications ===
[[Selective estrogen receptor modulator]]s (SERMs) reduce the risk of breast cancer but increase the risk of [[thromboembolism]] and [[endometrial cancer]].<ref name=Nelson2013 /> There is no overall change in the risk of death.<ref name="Nelson2013">{{cite journal | vauthors = Nelson HD, Smith ME, Griffin JC, Fu R | title = Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force | journal = Annals of Internal Medicine | volume = 158 | issue = 8 | pages = 604–14 | date = April 2013 | pmid = 23588749 | doi = 10.7326/0003-4819-158-8-201304160-00005 | doi-access = free }}</ref><ref name="Cuzick2013">{{cite journal | vauthors = Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL | title = Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data | journal = Lancet | volume = 381 | issue = 9880 | pages = 1827–34 | date = May 2013 | pmid = 23639488 | pmc = 3671272 | doi = 10.1016/S0140-6736(13)60140-3 }}</ref> They are thus not recommended for the prevention of breast cancer in women at average risk but it is recommended they be offered for those at high risk and over the age of 35.<ref>{{cite journal | vauthors = Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB | title = Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement | journal = JAMA | volume = 322 | issue = 9 | pages = 857–867 | date = September 2019 | pmid = 31479144 | doi = 10.1001/jama.2019.11885 | doi-access = free }}</ref> The benefit of breast cancer reduction continues for at least five years after stopping a course of treatment with these medications.<ref name="Cuzick2013" /> [[Aromatase inhibitor]]s (such as [[exemestane]] and [[anastrozole]]) may be more effective than SERMs (such as tamoxifen) at reducing breast cancer risk and they are not associated with an increased risk of endometrial cancer and thromboembolism.<ref>{{cite journal | vauthors = Mocellin S, Goodwin A, Pasquali S | title = Risk-reducing medications for primary breast cancer: a network meta-analysis | journal = The Cochrane Database of Systematic Reviews | volume = 2019 | pages = CD012191 | date = April 2019 | issue = 4 | pmid = 31032883 | pmc = 6487387 | doi = 10.1002/14651858.cd012191.pub2 }}</ref>